EQ vs OESX Comparison

Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.

Orion Energy Systems Inc is engaged in light-emitting diode lighting systems, wireless Internet of Things-enabled control solutions, project engineering, energy project management design, maintenance services, and turnkey electric vehicle charging stations and related installation services to commercial and industrial businesses, and federal and local governments, predominantly in North America. The group has three segments: the Orion lighting segment, the Orion maintenance segment, and the Orion electric vehicle charging segment. It generates the majority of its revenue from the Orion lighting segment, which develops and sells lighting products and provides construction and engineering services for Orion's commercial lighting and energy management systems.